| HOME | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|---|
| ||||||||||||||||||||||||||||||||
1 Division of Geriatrics
2 Division of Cardiology, Department of Medicine, Westchester Medical Center/New York Medical College, Valhalla.
3 Department of Medicine, University of Texas School of Medicine at Houston.
Background. Increased plasma homocysteine has been associated with atherosclerotic vascular disease in elderly persons. The Framingham Study found that plasma homocysteine was a risk factor for dementia and Alzheimer's disease.
Methods. We investigated in an academic nursing home the association of plasma homocysteine with atherosclerotic vascular disease plus dementia (group 1), atherosclerotic vascular disease without dementia (group 2), dementia without atherosclerotic vascular disease (group 3), and no dementia or atherosclerotic vascular disease (group 4).
Results. The mean plasma homocysteine level was 15.3 ± 3.0 µmol/L in 50 group 1 patients, 15.1 ± 2.7 µmol/L in 50 group 2 patients, 14.4 ± 2.7 µmol/L in 50 group 3 patients, and 10.6 ± 3.2 µmol/L in 50 group 4 patients (p <.0001 for group 1 vs group 4, for group 2 vs group 4, and for group 3 vs group 4).
Conclusions. The mean plasma homocysteine level was significantly higher in elderly patients with atherosclerotic vascular disease plus dementia, atherosclerotic vascular disease without dementia, and dementia without atherosclerotic vascular disease than in patients with no dementia or atherosclerotic vascular disease.
This article has been cited by other articles:
 |
|
 |
|
  G. Ravaglia, P. Forti, F. Maioli, M. Martelli, L. Servadei, N. Brunetti, E. Porcellini, and F. Licastro Homocysteine and folate as risk factors for dementia and Alzheimer disease Am. J. Clinical Nutrition, September 1, 2005; 82(3): 636 - 643. [Abstract] [Full Text] [PDF]
|
|
| HOME | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|---|
